Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-05-16
1991-04-30
Springer, David B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K47118
Patent
active
050118463
ABSTRACT:
The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of a medicament for the treatment of anxiety, psychosis, glaucoma and for the stimulation of gastric motility.
REFERENCES:
Hyperactivity Following Withdrawal of Mesolimbic Dopamine Infusion and Neuroleptic Treatment is Reversed by GR380231, British Journal of Pharmacology, vol. 91, p. 338 P, (1987).
More on Beecham's 5HT Compounds, Scrip, No. 1193, p. 28, (Apr. 3rd 1987).
Increased Gut Cholinergic Activity and Antagonism of 5-Hydroxytryptamine M-Receptors by BRL 24924; Potential Clinical Importance of BRL 24924: Potential clinical Importance of BRL 24924, Br. J. pharmac., vol. 91, p. 77 (1987).
Effects of the 5HT.sub.3 Receptor Antagonists, GR 3803F, on Raised Dopaminergic Activity in the Mesolimibic System of the Rat and Marmoset Brain, British Journal of Pharmacology, vol. 92, pp. 881-894, (1987).
Research, High Hopes for Glaxo Drug, but Early Days Yet, The Pharmaceutical Journal, p. 14, Jan. 3, 1987.
Anxiogenesis Follows Abstinence Withdrawal from Long-Term Treatment with Diazepam but not GR 38032F, British Journal of Pharmacology, vol. 90, p. 420 P, (Mar. 1987).
The Anxiolytic Activities of GR 38032F, A 5HT.sub.3 Receptor Antagonists, in the Rat and Cynomolgus Monkey, British Journal of Pharmacology, vol. 90, p. 88P, (Mar. 1987).
The Anxiolytic Activities of 5HT.sub.3 Antagonists in Laboratory Annimals, Neuroscience Letter, Supp. 29, p. S 68, (1987).
The Antipsychotic Potential of GR 38032F, a Selective 5HT.sub.3 Antagonist, Neuroscience Letter, Supp. 29, p. S 69 (1987).
Cheng Hsien
Fozard John R.
Gittos Maurice W.
Miller Francis P.
Moser Paul
Dixon J. Michael
Merrell Dow Pharmaceuticals Inc.
Springer David B.
LandOfFree
Medicament compositions derived from quinolizine and quinolizino does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicament compositions derived from quinolizine and quinolizino, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicament compositions derived from quinolizine and quinolizino will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-640583